Curriculum Vitae

Personal information

Robin Svensson

Work experience

1. Employer: Swedish Medical Products Agency
   - Start date: 122021
   - End date:
   - Position: Pharmacometric Assessor
   - Activities: Contributing to review processes for drugs, with focus on pharmacokinetics and pharmacometrics.
   - Country: Sweden
2. Employer: Pharmetheus AB
   - Start date: 052019
   - End date: 112021
   - Position: MIDD Consultant
   - Activities: Hands-on application of pharmacometric approaches to support drug development in various therapeutic areas.
   - Country: Sweden
3. Employer: Pharmetheus AB
   - Start date: 112017
   - End date: 042018
   - Position: Consultant
   - Activities: Hands-on application of pharmacometric approaches to support drug development in various therapeutic areas, during a six-month internship.
   - Country: Sweden

Education and training

1. Subject: Uppsala University
   - Start date: 102013
   - End date: 052019
   - Qualification: PhD in Pharmaceutical Science
   - Organisation: Pharmacokinetic and pharmacokinet-pharmacodynamic modelling for anti-tuberculosis drugs.
   - Country: Sweden
2. Subject: Uppsala University
   - Start date: 012009
   - End date: 062013
   - Qualification: Master Programme in Pharmacy
   - Organisation: No formal degree awarded. Studied 4.5 years at the programme which was the formal requirement at the time to become a PhD student.
   - Country: Sweden

Additional information

Publications

Application of the Multistate Tuberculosis Pharmacometric model in patients with rifampicin-treated pulmonary tuberculosis. Svensson RJ, Simonsson USH. Published in CPT:PSP 2016.

Improved power for Phase IIa trials using a model-based pharmacokineticpharmacodynamic approach compared with commonly used analysis methods. Svensson RJ, Gillespie SH, Simonsson USH. Published in JAC 2017.

A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses. Svensson RJ, Aarnoutse RE, et al. Published in CPT 2018.

Improving treatment outcome assessment in a mouse tuberculosis model. Mourik BC, Svensson RJ, et al. Published in Sci Rep 2018.

Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations. Svensson RJ, Svensson EM, et al. Published in JID 2018.

The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. Svensson EM, Svensson RJ, et al. Published in CID 2018.

Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis. Svensson RJ, Niward K, et al. Published in BJCP 2019.

Model-based relationship between the molecular bacterial load assay and time_topositivity in liquid culture. Svensson RJ, Sabiiti W, et al. Published in AAC 2019.

Rifampicin can be given as flat-dosing instead of weight-band dosing. Susanto BO, Svensson RJ, et al. Published in CID 2020.

Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires. Svensson RJ, Ribbing J, et al. Published in CPT:PSP 2021.

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions. Faraj A, Clewe O, Svensson RJ, et al. Published in Sci Rep 2020.

The population PKPD of unacylated and acylated ghrelin following single rising doses of BI 1356225 in healthy subjects is impacted by the time since last meal. Svensson RJ, Henrich A, et al. Presented at PAGE 2021 www.page_meeting.org/?abstract=9806.

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients. Faraj A, Svensson RJ, et al. Published in AAC 2020.

Population pharmacokinetics and exposure-response relationships of astegolimab in patients with severe asthma. Kotani N, Dolton M, Svensson RJ, et al. Published in JCP 2022.

Efficient and relevant stepwise covariate model building for pharmacometrics. Svensson RJ, Jonsson EN. Published in CPT:PSP 2022.

Rituximab PK and PKPD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity. Svensson RJ, Ooi QX, Friberg LE, et al. Published in CPT:PSP 2022.

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development. Ayoun Alsoud R, Svensson RJ, Svensson EM, et al. Published in Front Pharmacol 2023.

Projects

- Reasearch project in statistical methodology for complex models as a sub-contractor for CONFIRMS (CONsortium For Innovation in Regulatory Medical Statistics)
  - Start date: 180425
  - End date:

Memberships

- Member of the Modelling and Simulation Operational Expert Group at the European Medicines Agency
  - Start date: 010423
  - End date: 010425

Other Relevant Information